Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESONATE-HD study of long-term immunogenicity of Kostaive versus Comirnaty in hemodialysis patients
jRCTs071260085Recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Oct 2026
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of fostamatinib and tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Neutralizing antibody titers at 24 weeks post-vaccination. Started Oct 2026; status: recruiting.
02
Drugs
fostamatinibtozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs071260085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071260085.